Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen’s Devices were showcased at the Arab Health Exhibition, the largest annual medical event in the Middle East.

* Ariana Adjani, co-founder of Fine Treatment, was invited to deliver a presentation about therapeutic Allen’s Devices clinically proven to dissolve kidney stones, treat the enlarged or inflamed prostate gland, and ease low back pain.

OXFORD, UK / ACCESSWIRE / March 17, 2024 / Novel Thermobalancing therapy and Allen’s Devices have shown exceptional efficacy and safety for various, highly wide-spread health conditions, such as benign prostatic hyperplasia (BPH), chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), kidney stone disease, and chronic low back pain. Fine Treatment‘s expert Ariana Adjani was invited to give a talk on thermobalancing treatment at the prestigious annual Arab Health Medical Expo, attended by over 50,000 visitors.

“Thermobalancing therapy is a unique, non-invasive treatment option that allows to avoid serious side effects and complications of different medications and surgeries. The data showing superior treatment outcomes has been presented to the diverse audience at Arab Health”, explains Fine Treatment’s co-founder Ariana Adjani. “Several clinical trials demonstrate high efficacy and safety of this therapy. Our wearable Dr Allen’s Devices have been successfully used to treat different health conditions, including benign prostatic hyperplasia, chronic prostatitis, low back pain, and kidney stones.”

How Thermobalancing therapy with Dr Allen’s Devices work

Dr Allen’s Devices need to be worn on the body. Their design applies naturally derived components, namely special thermoelements, to the projection of the affected area or organs of the body to the skin. Dr Allen’s Devices should stay on the body for a prolong period of time, and they are specifically designed to cause no harm. While troubling symptoms ease fast, the actual treatment takes time. For instance, BPH treatment with Dr Allen’s Device can take 6 months or longer, chronic prostatitis and chronic low back pain can take 1-6 months, and the time to dissolve kidney stones depends on their initial size, with results evident from as little as 3 months.

The design of Dr Allen’s Devices incorporates a different number of thermoelements depending on the health condition it is intended to treat. One thermoelement is used to treat BPH, chronic prostatitis, and back pain, while 2 thermoelements are used to treat renal calculi in both kidneys simultaneously.

Thermobalancing therapy clinical trials outcomes

Research shows that Dr Allen’s Devices stimulate blood circulation naturally leading to the reduction of pain or other troubling symptoms, and to the subsequent treatment of diseases.

In patients with BPH, Dr Allen’s Device:

  • Reduces the size of benign tumour of the prostate gland,
  • Decreases nasty urinary symptoms, known as lower urinary tract symptoms (LUTS), such as sudden and frequent urges to pee, a weak stream, or a feeling like one can’t empty the bladder.

In patients with chronic prostatitis, Dr Allen’s Device:

  • Dramatically reduces chronic pelvic pain,
  • Decreases troubling urinary symptoms.

In men and women with lower back pain, triggered by either lumbar disk herniation (slipped disk) or non-specific causes, Dr Allen’s Device:

  • Significantly relieves pain,
  • Eases stiffness, comforts standing, improves walking ability and mobility.

In male and female patients with kidney stones, Dr Allen’s Device:

  • Dissolves the stones gradually, without renal colic,
  • Provides non-invasive treatment for any type and size of kidney stones.

Quality of life improvement with Dr Allen’s Devices

All clinical studies on Thermobalancing therapy with Dr Allen’s Devices demonstrate a major improvement of the quality of life of patients treated with this medtech solution. No adverse events have ever been observed in men and women involved in these clinical studies. Thermobalancing therapy and Dr Allen’s Devices are totally safe and can be used by people at home, helping to avoid serious side effects and complications of various medications and surgical procedures.

Ariana Adjani presented this new patient data at the Arab Health Medical Expo in Dubai. Invited by the Conference Producer Zohaib Meghji, she demonstrated how thermobalancing therapy can help to extend healthspan and stimulate longevity in patients affected by chronic diseases.

Ariana Adjani also attended the Future Health Summit held at the Museum of the Future in Dubai in conjunction with Arab Health. Invited by Mohamad Sabri, Strategic Partnership Director at Informa Markets, Ariana Adjani met with different healthcare industry stakeholders and discussed novel medical technologies, including thermobalancing therapy with Dr Allen’s Devices, that will have a significant impact on population health in the future.

Fine Treatment, a British R&D and medtech company leading the development of Dr Allen’s Devices, was welcomed at Arab Health Expo’s UK Healthcare Pavilion by Barbara Hollyhead and Mark Oakes, trade advisers at the UK Department for Business and Trade. Fine Treatment company profile on great.gov.uk showcases its ground-breaking achievements in the healthcare industry.

Contact Information:

Alex Day
Customer Service Manager
Fine Treatment, Oxford, United Kingdom
Tel.: +447958878300
Email: info@finetreatment.com
www.finetreatment.com

SOURCE: Fine Treatment

View the original press release on accesswire.com

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

4 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

5 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

5 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

6 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago